Armata's Net Loss Doubles to $49.5M, Raising Going Concern Doubts

TL;DR

**Armata's cash is drying up, and with a doubled net loss and a 'going concern' warning, this stock is a high-risk gamble on future financing.**

AI Summary

Armata Pharmaceuticals, Inc. (ARMP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $49.5 million, compared to $21.5 million for the same period in 2024. This substantial loss was primarily driven by a negative change in the fair value of its Convertible Loan, which swung from a gain of $17.3 million in 2024 to a loss of $15.2 million in 2025, and increased interest expense of $11.8 million in 2025, up from $7.5 million in 2024. The company's cash and cash equivalents stood at $14.8 million as of September 30, 2025, which is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. Grant and award revenue decreased slightly to $3.8 million for the nine months ended September 30, 2025, from $3.9 million in 2024, while research and development expenses also decreased to $17.6 million from $26.0 million. The company secured two new loans from Innoviva Strategic Opportunities LLC in 2025: a $15.0 million loan in August and a $10.0 million loan in March, both bearing 14.0% annual interest, to address its liquidity needs.

Why It Matters

Armata's escalating net loss and explicit 'going concern' warning signal severe financial distress for investors, potentially leading to significant stock price volatility or even delisting. The company's reliance on its principal stockholder, Innoviva, for high-interest debt financing (14.0% annual rate) highlights its limited access to capital and precarious financial position, impacting its ability to fund critical bacteriophage therapy development. For employees, this raises job security concerns, while customers and the broader market face uncertainty regarding the future of Armata's antibiotic-resistant treatment pipeline, especially given the global threat of antibiotic resistance. Competitively, this financial instability could allow rivals to gain ground in the bacteriophage therapeutics space.

Risk Assessment

Risk Level: high — The company explicitly states that its existing cash and cash equivalents of $14.8 million as of September 30, 2025, are 'not sufficient to fund its operations for the next 12 months,' raising 'substantial doubt about the Company's ability to continue as a going concern.' This is further exacerbated by an accumulated deficit of $377.2 million and a net loss of $49.5 million for the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the explicit 'going concern' warning and significant accumulated deficit indicate a high probability of further dilution or financial restructuring. New investors should avoid ARMP until a clear, sustainable financing plan is demonstrated and the going concern risk is mitigated.

Financial Highlights

debt To Equity

N/A

revenue

$3.8M

operating Margin

N/A

total Assets

$89.5M

total Debt

$259.3M

net Income

-$49.5M

eps

-$1.37

gross Margin

N/A

cash Position

$14.8M

revenue Growth

-2.5%

Revenue Breakdown

Key Numbers

• $49.5M — Net Loss (for the nine months ended September 30, 2025, significantly increased from $21.5M in 2024)
• $14.8M — Cash and Cash Equivalents (as of September 30, 2025, insufficient to fund operations for 12 months)
• $377.2M — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• $15.2M — Change in fair value of Convertible Loan (negative impact for the nine months ended September 30, 2025, compared to a $17.3M gain in 2024)
• $11.8M — Interest Expense (for the nine months ended September 30, 2025, up from $7.5M in 2024)
• $15.0M — August 2025 Loan (new loan from Innoviva Strategic Opportunities LLC)
• $10.0M — March 2025 Loan (new loan from Innoviva Strategic Opportunities LLC)
• 14.0% — Annual Interest Rate (on both the August 2025 and March 2025 loans)
• $17.6M — Research and Development Expenses (for the nine months ended September 30, 2025, decreased from $26.0M in 2024)
• $3.8M — Grant and Award Revenue (for the nine months ended September 30, 2025, slightly down from $3.9M in 2024)

Key Players & Entities

• Armata Pharmaceuticals, Inc. (company) — clinical-stage biotechnology company
• Innoviva Strategic Opportunities LLC (company) — lender and principal stockholder
• Innoviva, Inc. (company) — parent company of Innoviva Strategic Opportunities LLC
• NYSE American (regulator) — exchange where ARMP common stock is traded
• U.S. Food and Drug Administration (regulator) — regulatory agency for product candidates
• Cystic Fibrosis Foundation (company) — collaboration partner
• U.S. Department of Defense (company) — collaboration partner and award provider
• Private Securities Litigation Reform Act of 1995 (regulator) — safe harbor protection for forward-looking statements
• Sarbanes-Oxley Act (regulator) — governs internal control over financial reporting

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: As of September 30, 2025, Armata Pharmaceuticals had $14.8 million in cash and cash equivalents, which is insufficient to fund operations for the next 12 months. This raises substantial doubt about the company's ability to continue as a going concern.
• Increasing Net Loss [high — financial]: The net loss for the nine months ended September 30, 2025, significantly increased to $49.5 million from $21.5 million in the prior year period. This was driven by a negative swing in the fair value of the Convertible Loan and higher interest expenses.
• Significant Interest Expense [high — financial]: Interest expense for the nine months ended September 30, 2025, was $11.8 million, a substantial increase from $7.5 million in the same period of 2024. This is exacerbated by new loans with a 14.0% annual interest rate.
• Convertible Loan Fair Value Volatility [medium — financial]: The company experienced a negative change in the fair value of its Convertible Loan of $15.2 million for the nine months ended September 30, 2025, a significant reversal from a gain of $17.3 million in the prior year period, impacting net loss.
• Dependence on External Financing [medium — operational]: The company has secured two new loans totaling $25.0 million from Innoviva Strategic Opportunities LLC in 2025 to address liquidity needs. This highlights a reliance on debt financing to sustain operations.
• Accumulated Deficit [high — financial]: As of September 30, 2025, Armata Pharmaceuticals has an accumulated deficit of $377.2 million, indicating a history of significant losses and a challenging path to profitability.
• Research and Development Expenses [medium — regulatory]: While R&D expenses decreased to $17.6 million from $26.0 million for the nine months ended September 30, 2025, continued investment is crucial for pipeline development and future revenue generation.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Armata Pharmaceuticals often rely on external financing and strategic partnerships to fund their operations and advance drug candidates through clinical trials. The competitive landscape is intense, with many companies vying for market share and investor capital.

Regulatory Implications

As a pharmaceutical company, Armata is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to obtain regulatory approval for drug candidates, or non-compliance with manufacturing standards can have severe financial and operational consequences. The company's ability to navigate these regulatory pathways is critical for its long-term viability.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Evaluate the progress and potential of the R&D pipeline.
3. Assess the impact of the Convertible Loan and new debt on financial health.

Key Dates

• 2025-09-30: End of Nine Months Reporting Period — Reported a net loss of $49.5 million and had $14.8 million in cash, raising going concern doubts.
• 2025-08-XX: Secured $15.0 million loan from Innoviva Strategic Opportunities LLC — Provided additional liquidity, but at a high 14.0% interest rate.
• 2025-03-XX: Secured $10.0 million loan from Innoviva Strategic Opportunities LLC — Provided additional liquidity, but at a high 14.0% interest rate.
• 2024-09-30: End of Nine Months Reporting Period (Prior Year) — Reported a net loss of $21.5 million, with a gain on Convertible Loan fair value.

Glossary

Convertible Loan

A loan that can be converted into equity of the issuing company under certain conditions. (Fluctuations in its fair value significantly impacted Armata's net loss, and it represents a substantial liability.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company's current financial state raises substantial doubt about its ability to continue as a going concern.)

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by profits. (Indicates a long history of unprofitability for Armata Pharmaceuticals.)

Fair Value

The price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. (Changes in the fair value of the Convertible Loan are a significant driver of the company's reported net income/loss.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Armata Pharmaceuticals has seen a substantial increase in its net loss, nearly doubling from $21.5 million to $49.5 million. This deterioration is primarily attributed to a significant negative swing in the fair value of its Convertible Loan and higher interest expenses, despite a reduction in operating expenses, particularly in R&D. Grant and award revenue saw a slight decrease. The company's liquidity position has worsened, with cash reserves insufficient for the next twelve months, necessitating new debt financing.

Key Financial Figures

• $0.01 — ge on which registered Common Stock , $0.01 par value per share ARMP NYSE Ameri
• $26.2 million — the expected use of proceeds from the $26.2 million DoD award; the effects of government r

Filing Documents

• armp-20250930x10q.htm (10-Q) — 1509KB
• armp-20250930xex31d1.htm (EX-31.1) — 15KB
• armp-20250930xex31d2.htm (EX-31.2) — 15KB
• armp-20250930xex32d1.htm (EX-32.1) — 8KB
• armp-20250930xex32d2.htm (EX-32.2) — 8KB
• armp-20250930x10q001.jpg (GRAPHIC) — 53KB
• 0001104659-25-110383.txt ( ) — 6806KB
• armp-20250930.xsd (EX-101.SCH) — 45KB
• armp-20250930_cal.xml (EX-101.CAL) — 50KB
• armp-20250930_def.xml (EX-101.DEF) — 179KB
• armp-20250930_lab.xml (EX-101.LAB) — 397KB
• armp-20250930_pre.xml (EX-101.PRE) — 318KB
• armp-20250930x10q_htm.xml (XML) — 1128KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations 7 Condensed Consolidated Statements of Stockholders' Deficit 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39

OTHER INFORMATION

PART II. OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 3. Defaults upon Senior Securities 39 Item 4. Mine Safety Disclosures 40 Item 5. Other Information 40 Item 6. Exhibits 40

SIGNATURES

SIGNATURES 42 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") and certain information incorporated herein by reference contain forward-looking statements, which are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to our future financial performance and involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or events to be materially different from any future results, performance, or events expressed or implied by the forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding: our estimates regarding anticipated operating losses, capital requirements and needs for additional funds; our ability to raise additional capital when needed and to continue as a going concern; our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials; our clinical development plans, including planned clinical trials; the expected timing of additional clinical trials, including Phase 1b/Phase 2 or registrational clinical trials; our research and development plans; our ability to select combinations of phages to formulate our product candidates; our development of bacteriophage-based therapies; the potential use of bacteriophages to treat bacterial infections; the potential future of antibiotic resistance; the ability for bacteriophage therapies to disrupt and destroy biofilms and restore sensitivity to antibiotics; the potential for bacteriophage technology being uniquely positioned to address the global threat of antibiotic resistance; our planned development strategy, presenting data to regulatory agencies and defining planned clinical studies; our ab

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

Item 1. FINANCIAL STATEMENTS Armata Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 14,756 $ 9,291 Prepaid expenses and other current assets 1,415 1,273 Other receivables 759 744 Total current assets 16,930 11,308 Restricted cash 5,390 5,480 Property and equipment, net 12,560 13,241 Operating lease right-of-use asset 39,917 41,687 In-process research and development 10,256 10,256 Goodwill 3,490 3,490 Other assets 973 975 Total assets $ 89,516 $ 86,437 Liabilities and stockholders' deficit Current liabilities Accounts payable and accrued liabilities $ 1,999 $ 2,055 Accrued compensation 1,843 2,280 Convertible Loan, current 48,088 — Term debt, current 82,992 38,954 Current portion of operating lease liabilities 4,525 4,431 Other current liabilities 503 529 Total current liabilities 139,950 48,249 Convertible Loan, non-current — 32,897 Term debt, non-current 15,240 22,539 Operating lease liabilities, net of current portion 26,837 27,694 Deferred tax liability 3,077 3,077 Total liabilities 185,104 134,456 Commitments and contingencies (Note 12) Stockholders' deficit Common Stock, $ 0.01 par value; 217,000,000 shares authorized; 36,229,842 and 36,183,067 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 362 362 Additional paid-in capital 281,286 279,354 Accumulated deficit ( 377,236 ) ( 327,735 ) Total stockholders' deficit ( 95,588 ) ( 48,019 ) Total liabilities and stockholders' deficit $ 89,516 $ 86,437 See accompanying notes to condensed consolidated financial statements. 6 Table of Contents Armata Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, exc

View Full Filing

View this 10-Q filing on SEC EDGAR